

## Supplementary Material

**Table S1.** Cyclic heptapeptides in the sponge *Stylissa caribica*.

**Table S2.** Full NMR data of stylissamide L (**1**) ( $^1\text{H}$  700 MHz,  $^{13}\text{C}$  175 MHz,  $\text{DMSO-}d_6$ ).

**Table S3.** Links to LC-MS data and molecular networks.

**Figure S1.** Molecular networks obtained using (a) the program MetGem (b) the Metabolomics workflow on GNPS, and (g) the Feature-Based Molecular Network workflow on GNPS.

**Figure S2.** Positive ion mode high-resolution ESI mass spectrum of stylissamide L (**1**).

**Figure S3.** Positive ion mode high-resolution ESI MS/MS spectrum of stylissamide L (**1**).

**Figure S4.**  $^1\text{H}$ -NMR spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S5.**  $^{13}\text{C}$ -NMR spectrum of stylissamide L (**1**) (175 MHz,  $\text{DMSO-}d_6$ ).

**Figure S6.** COSY spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S7.** TOCSY spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S8.** Spin systems of stylissamide L (**1**) from the sections of the TOCSY spectrum.

**Figure S9.** NOESY spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S10.** HSQC spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S11.** HMBC spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S12.** Band-selective HMBC spectrum of stylissamide L (**1**) (700 MHz,  $\text{DMSO-}d_6$ ).

**Figure S13.** UV and ECD spectra of stylissamide L (**1**) in ACN.

**Figure S14.** Real time monitoring of cancer cell proliferation after exposure to stylissamide L (**1**).

**Figure S15.** Real-time monitoring of 3AB-OS and MCF-7 cell migration after exposure to stylissamide L (**1**).

**Table S1.** Cyclic heptapeptides in the sponge *Stylissa caribica*.

Cyclic peptide	[M+H] <sup>+</sup>	Exact Mass	Retention time	Retention time	Citation
			RP-18 <sup>a</sup>	PFP <sup>b</sup>	
Stylissamide A	C <sub>44</sub> H <sub>61</sub> N <sub>8</sub> O <sub>9</sub>	845.4556	1.72	26.34	<i>c,d,e</i>
Stylissamide B	C <sub>44</sub> H <sub>58</sub> N <sub>7</sub> O <sub>8</sub>	812.4341	ND	ND	<i>c,d,e</i>
Stylissamide C	C <sub>48</sub> H <sub>60</sub> N <sub>7</sub> O <sub>8</sub>	862.4498	20.29	32.66	<i>c,d,e</i>
Stylissamide D	C <sub>45</sub> H <sub>62</sub> N <sub>7</sub> O <sub>8</sub>	828.4654	19.55	32.48	<i>c,d,e</i>
Stylissamide E	C <sub>39</sub> H <sub>59</sub> N <sub>8</sub> O <sub>9</sub>	783.4400	13.29	28.76	<i>d,e</i>
Stylissamide F	C <sub>43</sub> H <sub>57</sub> N <sub>10</sub> O <sub>9</sub>	857.4304	13.94	32.21	<i>d,e</i>
Stylissamide G	C <sub>45</sub> H <sub>62</sub> N <sub>7</sub> O <sub>7</sub>	812.4705	ND	ND	<i>e</i>
Stylissamide H	C <sub>44</sub> H <sub>59</sub> N <sub>8</sub> O <sub>8</sub>	827.4450	ND	ND	<i>e</i>
Stylissamide L	C <sub>41</sub> H <sub>53</sub> N <sub>8</sub> O <sub>10</sub>	817.3876	6.21	24.95	this work
Hymenamide C	C <sub>43</sub> H <sub>55</sub> N <sub>8</sub> O <sub>9</sub>	827.4087	20.71	32.58	<i>f</i>
Hymenamide F	C <sub>35</sub> H <sub>61</sub> N <sub>10</sub> O <sub>8</sub> S	781.4389	1.67	26.40	<i>f</i>
Phakellistatin 3	C <sub>42</sub> H <sub>55</sub> N <sub>8</sub> O <sub>9</sub>	815.4087	18.50	31.89	<i>h</i>
Phakellistatin 13	C <sub>42</sub> H <sub>55</sub> N <sub>8</sub> O <sub>8</sub>	799.4137	20.09	32.47	<i>g</i>
Stylisin 1	C <sub>45</sub> H <sub>62</sub> N <sub>7</sub> O <sub>8</sub>	828.4654	ND	ND	<i>c,d,e,g</i>
Stylisin 2	C <sub>44</sub> H <sub>58</sub> N <sub>7</sub> O <sub>8</sub>	812.4341	ND	ND	<i>c,d,e,g</i>

- a.* Experiments were performed with a Kinetex 5  $\mu$ m, 50 mm  $\times$  2.10 mm C18 column using a flow rate of 200  $\mu$ L/min and the following elution gradient: 10% MeOH for 1 min, 10%–100% MeOH over 30 min, and 100% MeOH for 10 min.
- b.* Experiments were performed with a Kinetex 5  $\mu$ m, 100 mm  $\times$  2.1 mm PFP column using a flow rate of 200  $\mu$ L/min and the same elution gradient of H<sub>2</sub>O and MeOH described above.
- c.* Schmidt, G.; Grube, A.; Köck, M. Stylissamides A-D - New proline-containing cyclic heptapeptides from the marine sponge *Stylissa caribica*. *European J. Org. Chem.* **2007**, *2*, 4103–4110, doi:10.1002/ejoc.200700013.
- d.* Cychon C.; Köck, M. Stylissamides E and F, Cyclic Heptapeptides from the Caribbean Sponge *Stylissa caribica*. *J. Nat. Prod.* **2010**, *73*, 738–742, doi: 10.1021/np900664f.
- e.* Wang, X.; Morinaka, B. I.; Molinski, T. F. Structures and solution conformational dynamics of stylissamides G and H from the Bahamian Sponge *Stylissa caribica*. *J. Nat. Prod.* **2014**, *77*, 625–630, doi:10.1021/np400891s.
- f.* Grube, A.; Maier, T.; Köck, M. MS-guided Fractionation as a Fast Way to the Identification of New Natural Products – MALDI-TOF-MS Screening of the Marine Sponge *Stylissa caribica*. *Zeitschrift für Naturforsch. B* **2007**, *62*, 600–604, doi:10.1515/znb-2007-0420..
- g.* Mohammed, R.; Peng, J.; Kelly, M.; Hamann, M.T. Cyclic heptapeptides from the Jamaican sponge *Stylissa caribica*. *J. Nat. Prod.* **2006**, *69*, 1739–1744, doi:10.1021/np060006n.
- h.* This compound was not previously detected in specimens of *Stylissa caribica*. It was putatively identified by the Dereplicator tool in GNPS.

Table S2. Full NMR data of stylissamide L (1) (<sup>1</sup>H 700 MHz, <sup>13</sup>C 175 MHz, DMSO-*d*<sub>6</sub>).

AA	pos.	δ <sub>c</sub> , type	δ <sub>H</sub> , mult ( <i>J</i> in Hz)	NOESY	HMBC
Pro <sup>I</sup>	1	170.3, C	-		
	2	59.1, CH	4.34, dd (5.1, 8.6)	Ser-NH, Tyr-NH, Phe-NH	Phe-1
	3	28.1, CH <sub>2</sub>	a 2.15, m b 1.75, m	Pro <sup>II</sup> -4b, Pro <sup>II</sup> -3a Pro <sup>II</sup> -2, Pro <sup>II</sup> -4b	Pro <sup>I</sup> -1 Pro <sup>I</sup> -1
	4	24.3, CH <sub>2</sub>	1.87, m		
	5	46.7, CH <sub>2</sub>	a 3.45, m b 3.36, m		Phe-1, Pro <sup>I</sup> -2
Pro <sup>II</sup>	1	171.8, C	-		
	2	60.1, CH	4.28, dd (1.5, 8.8)	Ser-NH, Pro <sup>I</sup> -2, Pro <sup>I</sup> -3b	Pro <sup>II</sup> -1, Pro <sup>II</sup> -5
	3	31.8, CH <sub>2</sub>	a 2.16, m b 2.00, m	Ser-NH Pro <sup>III</sup> -3a	Pro <sup>II</sup> -1
	4	21.7, CH <sub>2</sub>	a 1.77, m b 1.57, m		
	5	46.8, CH <sub>2</sub>	a 3.60, ddd (1.5, 8.4, 10.8) b 3.33, ddd (10.8, 10.8, 7.1) 7.65, d (5.9)	Ser-NH Pro <sup>III</sup> -4b Tyr-NH, Pro <sup>I</sup> -2, Pro <sup>II</sup> -2, Pro <sup>II</sup> -5a, Pro <sup>II</sup> -4b	Pro <sup>I</sup> -1 Pro <sup>II</sup> -1
Ser	NH				
Tyr	1	167.7, C	-		
	2	60.0, CH	3.85, ddd (3.6, 5.9, 10.2)	Tyr-NH	Ser -1
	3	60.9, CH <sub>2</sub>	a 3.46, dd (10.2, 11.9) b 3.14, dd (11.9, 3.6) 7.34, d (9.1)	Tyr-NH, Tyr-5/9	
	NH			Ser-NH, Ser-3a	Ser-1
	1	171.5 C	-		
Pro <sup>III</sup>	2	51.5 CH	4.88 ddd (3.2, 9.1, 10.9)	Pro <sup>III</sup> -5a/b	Tyr- 1
	3	37.0 CH <sub>2</sub>	a 3.35, dd (3.2, 13.5) b 2.42, dd (10.9, 13.5)	Pro <sup>III</sup> -5a/b, Phe-NH, Gln-NH Gln-NH, Phe-NH, Pro <sup>III</sup> -5a	Tyr-5/9 Tyr-1, Tyr-4
	4	126.6 C	-		
	5/9	130.5 CH	7.08, d (8.5)	Tyr-3a, Tyr-3b	Tyr-7
	6/8	114.9 CH	6.66, d (8.5)		Tyr-7
Gln	7	156.0 C	-		
	7-OH		7.42, s		
	1	171.9, C	-		
	2	63.1, CH	4.06, t (8.7)	Phe-NH,	Pro <sup>III</sup> -1
	3	28.7, CH <sub>2</sub>	a 2.22 m b 1.81, m	Gln-NH	Pro <sup>III</sup> - 1
Phe	4	25.0, CH <sub>2</sub>	a 2.11, m b 1.98, m	Gln-NH, Gln-3a, Gln-3b	
	5	46.9, CH <sub>2</sub>	a 3.93, ddd (6.8, 9.8, 9.8) b 3.82, m 8.17, d (7.0)	Tyr-2, Tyr-3a Tyr-2, Gln-NH, Tyr-3a Phe-NH, Tyr-3a, Pro <sup>III</sup> -2, Pro <sup>III</sup> -3b, Pro <sup>III</sup> -4a	Pro <sup>III</sup> -3 Pro <sup>III</sup> -1
	NH				
	1	170.7, C	-		
	2	52.8, CH	4.05, ddd (4.3, 7.0, 10.0)	Phe-NH, Pro <sup>III</sup> -4b	Gln-1
Phe	3	25.9, CH <sub>2</sub>	a 1.85, m b 1.73, m	Pro <sup>III</sup> -4a Pro <sup>III</sup> - 4a	Gln-1, Gln-5 Gln-5
	4	31.5, CH <sub>2</sub>	a 2.13, ddd (7.2, 15.7, 7.2) b 2.04, ddd (7.2, 15.7, 7.2)	Pro <sup>III</sup> -5b, Pro <sup>III</sup> -3a, Pro <sup>III</sup> -3b Pro <sup>III</sup> -4a	Gln-5 Gln-5
	5	174.5, C	-		
	5-NH <sub>2</sub>		6.92, s	Gln-4a, Gln-4b	Gln-5
	NH		7.11, d (7.2)	Phe-2, Gln-NH, Pro <sup>III</sup> -2, Pro <sup>I</sup> -5b, Tyr-NH	Gln-1
Phe	1	167.5 C	-		
	2	51.5, CH	4.69, ddd (5.8, 7.2, 8.0)	Pro <sup>I</sup> -5a, Pro <sup>I</sup> -5b	Phe-1, Phe-4
	3	36.9 CH <sub>2</sub>	a 3.18, dd (8.0, 14.2) b 2.71 (5.8, 14.2)		Phe-1, Phe-4 Phe-1, Phe-5/9
	4	138.0, C	-		
	5/9	128.9, CH	7.16, d (7.5)		
Phe	6/8	126.0, CH	7.18, t (7.3)		
	7	128.0, CH	7.22, t (7.5)		

Table S3. Links to LC-MS data and molecular networks.

Description	Link
Classical Molecular Networking (Metabolomics) workflow	<a href="https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=4acb49028d7041c39fccf03dd6e8c195">https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=4acb49028d7041c39fccf03dd6e8c195</a>
Feature-Based Molecular Networking workflow	<a href="https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=db7aa9e8bec64d6290cc040254f00b87">https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=db7aa9e8bec64d6290cc040254f00b87</a>
Dereplicator	<a href="https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f8b123b5ea89494481549c1a519caf5d">https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=f8b123b5ea89494481549c1a519caf5d</a>
LC-MS data on Massive	<a href="https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=f77c49cb5d73489583c08d3e66b558e1">https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=f77c49cb5d73489583c08d3e66b558e1</a> FTP access: ftp://MSV000085904@massive.ucsd.edu password: Sty_reviewers




Figure S1. Molecular networks of the extract of *S. caribica* obtained with the same data and the same parameters ( $m/z$  tolerance 0.01 Da, cosine score > 0.55, matched peaks > 8, maximum number of neighbor nodes = 10) using (a) the program MetGem (b) the Metabolomics workflow on GNPS, and (c) the Feature-Based Molecular Network workflow on GNPS.




Figure S2. Positive ion mode high-resolution ESI mass spectrum of stylissamide L (1).




Figure S3. Positive ion mode high-resolution ESI MS/MS spectrum of stylissamide L (1).




Figure S4.  $^1\text{H}$ -NMR spectrum of stylissamide L (1) (700 MHz,  $\text{DMSO}-d_6$ ).




Figure S5.  $^{13}\text{C}$ -NMR spectrum of stylissamide L (1) (175 MHz,  $\text{DMSO}-d_6$ ).




Figure S6. COSY spectrum of stylissamide L (1) (700 MHz, DMSO-*d*<sub>6</sub>).






Figure S7. TOCSY spectrum of stylissamide L (1) (700 MHz, DMSO-*d*<sub>6</sub>).




Figure S8. Spin systems of stylissamide L (1) from the sections of the TOCSY spectrum.




Figure S9. NOESY spectrum of stylissamide L (1) (700 MHz, DMSO- $d_6$ ).




Figure S10. HSQC spectrum of stylissamide L (1) (700 MHz,  $\text{DMSO}-d_6$ ).




Figure S11. HMBC spectrum of stylissamide L (1) (700 MHz, DMSO- $d_6$ ).




Figure S12. Band-selective HMBC spectrum of stylissamide L (1) (700 MHz,  $\text{DMSO}-d_6$ ).







Figure S13. UV and ECD spectra of stylissamide L (1) in ACN.



**Figure S14.** Real time monitoring of cancer cell proliferation after exposure to stylissamide L (**1**) and DMSO vehicle, by using the xCELLigence System Real-Time Cell Analyzer. (**A,D**) Normalized cell index (NCI) traces of MCF7 (**A**) and BxPC-3 (**D**) cells treated with different concentrations (6.25, 12.5, 25, and 50  $\mu$ M) of stylissamide L (**1**) and DMSO vehicle (0.1%) for 72 hours. Black arrow shows the start of drug treatment. Each cell index value was normalized at this time. (**B,E**) Slope values of growth curves of MCF-7 (**B**) and BxPC-3 (**E**) cells after 72 h exposure to different concentrations (6.25, 12.5, 25, and 50  $\mu$ M) of stylissamide L (**1**) and DMSO vehicle (0.1%). NCI slope values are relative to controls treated with DMSO vehicle. (**C,F**) Doubling times of NCI of MCF-7 (**C**) and BxPC-3 (**F**) cells after 72 h treatment with different concentrations (6.25, 12.5, 25, and 50  $\mu$ M) of stylissamide L (**1**) and DMSO (0.1%). Data are presented as mean  $\pm$  SD;  $n=3$ . Statistical significances are referred to the DMSO control. One-way analysis of variance (ANOVA) was applied to compare means of groups and Dunnett's method was used as a post-hoc test to compare multiple groups versus the control group.  $p$ -values  $< 0.05$  were considered to be statistically significant. Statistical analysis was performed using the GraphPad Prism Software Version 5. \*  $p < 0.05$ .





**Figure S15.** Real-time monitoring of 3AB-OS and MCF-7 cell migration after exposure to stylissamide L (**1**). (A,C) NCI traces of 3AB-OS (A) and MCF-7 (C) cells seeded with compound **1** or DMSO (0.1%) vehicle, in presence of 10% Fetal Bovine Serum (FBS) as the chemoattractant. Migration was monitored for 20 hours, using the xCELLigence System equipped with specially designed 16-well plates (CIM-plate 16). (B,D) Migration activity of 3AB-OS (B) and MCF-7 (D) cells seeded with compound **1** or DMSO (0.1%) vehicle, in presence of 10% Fetal Bovine Serum (FBS) as the chemoattractant. Cell migration rates were recorded for 20 hours and expressed as slope values of NCI curves. Data are presented as mean  $\pm$  SD; n=3. Statistical significances are referred to the DMSO control. Two-group comparisons were performed using Student's t-test. P-values < 0.05 were considered to be statistically significant. Statistical analysis was performed using the GraphPad Prism Software Version 5.